Helus Pharma Inc.
HELP | NASDAQ
$10.60
-$0.11 (-1.03%)
At close: Oct 30, 2026, 4:00 PM ET
$11.00
+$0.40 (+3.77%)
Pre-market:
Nov 2, 2026, 4:02 AM ET
-1.03%
(1D)No price chart data available for 1D timeframe.
Rating
28.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #832/1028 (Top 81%)
Key Statistics
Market Data
Market Cap $656.72M
1D Range
10.42 10.97
52W Range
3.87 14.02
Valuation (TTM)
PE -1.92
PB 2.72
EV/EBITDA -2.77
Valuation (NTM)
Forward PE N/A
Forward PEG 0.08
Price Target $22.00
Cash Flow
FCF Yield -23.5%
SBC Adj. FCF Yield -24.3%
SBC Impact -3.2%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y -151.6% |
-102.2%
Dil EPS 3Y | 5Y 12.1% |
25.7%
FCF 3Y | 5Y -34.3% |
-30.3%
Returns
ROA -67.6%
ROE -74.5%
ROIC -70.8%
Financial Health
Net Cash
$166.17M
Current Ratio 10.97
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Helus Pharma is a clinical-stage pharmaceutical company developing proprietary serotonergic agonists for mental health conditions. Its pipeline includes HLP003, in Phase 3 development for adjunctive t...
Sector Healthcare
Industry Medical - Pharmaceuticals
Employees 100
IPO Date Sep 13, 2019
Website www.helus.com
Fiscal Year April - March
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$16.00
Upside
+50.94%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove HELP